EVLO — Evelo Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $16.69m
Annual income statement for Evelo Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 58.1 | 86.4 | 91.9 | 119 | 109 |
| Operating Profit | -58.1 | -86.4 | -91.9 | -119 | -109 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -56.9 | -85.3 | -93.3 | -122 | -114 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -56.9 | -85.5 | -93.7 | -122 | -115 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -56.9 | -85.5 | -93.7 | -122 | -115 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -60.9 | -85.5 | -93.7 | -122 | -115 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -38.2 | -53.4 | -47.5 | -45.4 | -26.2 |